Evotec (NASDAQ:EVO) Shares Up 10.8% on Better-Than-Expected Earnings

Key Points

• Evotec shares rose 10.8% after its quarterly results exceeded expectations, with trading volume also above average.
• The company reported a loss of $0.11 per share, narrower than the $0.18 consensus loss, and revenue of $186.81 million versus estimates of $165.34 million; base-business net sales in D&PD rose 24%.
• Despite the quarterly improvement, Evotec remains unprofitable, and its reduced 2030 revenue target has raised questions about its longer-term growth and recovery.

Shares of Evotec AG (NASDAQ:EVO - Get Free Report) shot up 10.8% on Thursday following a better than expected earnings announcement. The company traded as high as $1.6853 and last traded at $1.74. 127,378 shares changed hands during mid-day trading, an increase of 26% from the average daily volume of 101,035 shares. The stock had previously closed at $1.57.

The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.07. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%. The business had revenue of $186.81 million for the quarter, compared to the consensus estimate of $165.34 million.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Evotec reported Q3 revenue of €164.9 million and adjusted EBITDA loss of €1.6 million. Separately, analyst-reported figures showed a loss of $0.11 per share, narrower than the $0.18 consensus loss, and revenue of $186.81 million versus estimates of $165.34 million. D&PD base-business net sales rose 24%, pointing to stronger commercial momentum. Evotec Q3 and nine-month results
• Neutral Sentiment: Restructuring is moving forward, but its eventual effect on costs and growth will depend on execution. Nine-month adjusted EBITDA remained negative at €44.3 million, underscoring that the quarterly improvement has not yet resolved broader profitability challenges. Evotec narrows Q3 EBITDA loss
• Negative Sentiment: Evotec cut its 2030 revenue target and tempered and slightly postponed medium-term goals. The lower outlook may limit the impact of the quarterly beat by raising questions about the pace of recovery and long-term growth. Evotec cuts 2030 revenue target

Analyst Ratings Changes

A number of equities analysts recently weighed in on EVO shares. Weiss Ratings lowered shares of Evotec from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 25th. Berenberg Bank downgraded Evotec from a "buy" rating to a "hold" rating in a report on Thursday, July 16th. TD Cowen cut shares of Evotec from a "buy" rating to a "hold" rating and set a $2.00 target price for the company. in a report on Wednesday, July 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $4.00 price target on shares of Evotec in a research report on Wednesday, October 14th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Evotec currently has a consensus rating of "Hold" and an average target price of $3.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Optiver Holding B.V. lifted its holdings in shares of Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company's stock valued at $709,000 after buying an additional 242,973 shares during the period. WCM Investment Management LLC grew its holdings in Evotec by 12.1% during the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company's stock worth $1,480,000 after acquiring an additional 67,917 shares during the period. Finally, Apollon Wealth Management LLC acquired a new position in Evotec during the first quarter worth $28,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Evotec Price Performance

The company has a 50-day simple moving average of $1.63 and a 200-day simple moving average of $2.49. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec's activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.